Feedback / Questions
Opdivo (nivolumab) - Ono Pharma, BMS
TG4010 - Transgene
Transgene: Corporate Presentation
(Transgene)
-
Jul 21, 2016 -
Anticipated preliminary data from P2 trial (NCT02823990) of TG4010 in combination with nivolumab for 2L NSCLC in 2017
Anticipated P2 data
•
Non Small Cell Lung Cancer • Oncology
http://www.transgene.fr/wp-content/uploads/2016/07/160719-Transgene_Corporate_Presentation_July2016.pdf
Jul 21, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious